Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry

Authors: Shiwu Wu, Lan Yu, Danna Wang, Lei Zhou, Zenong Cheng, Damin Chai, Li Ma, Yisheng Tao

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

To investigate on expressions and clinical significances of CD133 protein and vasculogenic mimicry (VM) in primary non-small cell lung cancer (NSCLC).

Methods

The specimens of NSCLC from 305 Chinese patients with follow-up were analyzed for CD133 protein expression and VM by immunohistochemical and histochemical staining.

Results

In NSCLC, positive rates of 48.9% and 35.7% were obtained for CD133 and VM, respectively. The VM and expression of CD133 were significantly higher in carcinoma than in normal. There were a positive relationship between the VM and expression of CD133 and the tumor grade, lymph node metastasis and clinical stage (all P<0.05). The overall mean survival time of the patients with CD133 and VM positive expression was lower than that of patients with negative expression. Microvessel density (MVD) was positive corresponded with the grade, lymph node metastasis and clinical stage (all P<0.05). The overall mean survival time of the patients with MVD≥22’s group was shorter than that of patients with MVD<22’s group. Pathological-tumor-node-metastasis (pTNM) stage, positive expression of CD133 and VM, postoperative therapy and MVD were independent prognostic factors of NSCLC (P<0.05). Immunohistochemistry revealed an important intratumoral heterogeneity in all four CD133 expression profiles.

Conclusions

VM, MVD and expression of CD133 are related to differentiation, lymph node metastasis, clinical stage, and prognosis. It is suggested that CD133, VM and MVD should be considered as a potential marker for the prognosis.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Center MM, DeSantis C, Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010, 19: 1893-1907. 10.1158/1055-9965.EPI-10-0437.CrossRefPubMed
2.
Ramalingam SS, Owonikoko TK, Khuri FR: Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin. 2011, 61: 91-112. 10.3322/caac.20102.CrossRefPubMed
3.
Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 2001, 414: 105-111. 10.1038/35102167.CrossRefPubMed
4.
Monk M, Holding C: Human embryonic genes re-expressed in cancer cells. Oncogene. 2001, 20: 8085-8091. 10.1038/sj.onc.1205088.CrossRefPubMed
5.
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature. 2004, 432: 396-401. 10.1038/nature03128.CrossRefPubMed
6.
7.
Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG: Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005, 65: 5506-5511. 10.1158/0008-5472.CAN-05-0626.CrossRefPubMed
8.
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA: Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007, 318: 1917-1920. 10.1126/science.1151526.CrossRefPubMed
9.
O’Brien CA, Pollett A, Gallinger S, Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007, 445: 106-110. 10.1038/nature05372.CrossRefPubMed
10.
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, DeMaria R: Identification and expansion of human colon cancer-initiating cells. Nature. 2007, 445: 111-115. 10.1038/nature05384.CrossRefPubMed
11.
Okita K, Ichisaka T, Yamanaka S: Generation of germline-competent induced pluripotent stem cells. Nature. 2007, 448: 313-317. 10.1038/nature05934.CrossRefPubMed
12.
Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ: Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008, 451: 141-146. 10.1038/nature06534.CrossRefPubMed
13.
Chiba T, Kamiya A, Yokosuka O, Iwama A: Cancer stem cells in hepatocellular carcinoma: recent progress and perspective. Cancer Lett. 2009, 286: 145-153. 10.1016/j.canlet.2009.04.027.CrossRefPubMed
14.
Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997, 90: 5002-5012.PubMed
15.
Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW: A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood. 1997, 90: 5013-5021.PubMed
16.
Niu CS, Li MW, Ni YF, Chen JM, Mei JM, Li J, Fu XM: Effect of all-trans retinoic acid on the proliferation and differentiation of brain tumor stem cells. J Exp Clin Cancer Res. 2010, 29: 113-10.1186/1756-9966-29-113.CrossRefPubMedPubMedCentral
17.
Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR: Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol. 2010, 8: 147-10.1186/1477-7827-8-147.CrossRefPubMedPubMedCentral
18.
Sagrinati C, Netti GS, Mazzinghi B, Lazzeri E, Liotta F, Frosali F, Ronconi E, Meini C, Gacci M, Squecco R, Carini M, Gesualdo L, Francini F, Maggi E, Annunziato F, Lasagni L, Serio M, Romagnani S, Romagnani P: Isolation and characterization of multipotent progenitor cells from the Bowman’s capsule of adult human kidneys. J Am Soc Nephrol. 2006, 17: 2443-2456. 10.1681/ASN.2006010089.CrossRefPubMed
19.
Janikova M, Skarda J, Dziechciarkova M, Radova L, Chmelova J, Krejci V, Sedlakova E, Zapletalova J, Langova K, Klein J, Grygarkova I, Kolek V: Identification of CD133+/Nestin+ putative cancer stem cells in non-small cell lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010, 154: 321-326. 10.5507/bp.2010.048.CrossRefPubMed
20.
Kordes C, Sawitza I, Müller-Marbach A, Ale-Agha N, Keitel V, Klonowski-Stumpe H, Häussinger D: CD133+ hepatic stellate cells are progenitor cells. Biochem Biophys Res Commun. 2007, 352: 410-417. 10.1016/j.bbrc.2006.11.029.CrossRefPubMed
21.
Yang ZL, Zheng Q, Yan J, Pan Y, Wang ZG: Upregulated CD133 expression in tumorigenesis of colon cancer cells. World J Gastroenterol. 2011, 17: 932-937. 10.3748/wjg.v17.i7.932.CrossRefPubMedPubMedCentral
22.
Zhao P, Li Y, Lu Y: Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer. 2010, 10: 218-10.1186/1471-2407-10-218.CrossRefPubMedPubMedCentral
23.
Zou J, Yu XF, Bao ZJ, Dong J: Proteome of human colon cancer stem cells: a comparative analysis. World Gastroenterol. 2011, 17: 1276-1285. 10.3748/wjg.v17.i10.1276.CrossRef
24.
Moriyama T, Ohuchida K, Mizumoto K, Cui L, Ikenaga N, Sato N, Tanaka M: Enhanced cell migration and invasion of CD133+ pancreatic cancer cells cocultured with pancreatic stromal cells. Cancer. 2010, 116: 3357-3368. 10.1002/cncr.25121.CrossRefPubMed
25.
Wang XY, Penalva LO, Yuan H, Linnoila RI, Lu J, Okano H, Glazer RI: Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. Mol Cancer. 2010, 9: 221-10.1186/1476-4598-9-221.CrossRefPubMedPubMedCentral
26.
Ito Y, Hamazaki TS, Ohnuma K, Tamaki K, Asashima M, Okochi H: Isolation of murine hair-inducing cells using the cell surface marker prominin-1/CD133. J Invest Dermatol. 2007, 127: 1052-1060. 10.1038/sj.jid.5700665.CrossRefPubMed
27.
Rentala S, Yalavarthy PD, Mangamoori LN: Alpha1 and beta1 integrins enhance the homing and differentiation of cultured prostate cancer stem cells. Asian J Androl. 2010, 12: 548-555. 10.1038/aja.2010.20.CrossRefPubMedPubMedCentral
28.
29.
Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe’er J, Trent JM, Meltzer PS, Hendrix MJ: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999, 155: 739-752. 10.1016/S0002-9440(10)65173-5.CrossRefPubMedPubMedCentral
30.
Forberg R, Hendrix MJ, Maniotis AJ: Vasculogenic mimicry and tumor angiogenesis. Am J Pathol. 2000, 156: 361-381. 10.1016/S0002-9440(10)64739-6.CrossRef
31.
Zhang S, Guo H, Zhang D, Zhang W, Zhao X, Ren Z, Sun B: Microcirculation patterns in different stages of melanoma growth. Onclo Rep. 2006, 15: 15-20.
32.
Fan YZ, Sun W: Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy. World J Gastrointest Surg. 2010, 2: 117-127. 10.4240/wjgs.v2.i4.117.CrossRefPubMedPubMedCentral
33.
Sun W, Fan YZ, Zhang WZ, Ge CY: A pilot histomorphology and hemodynamic of vasculogenic mimicry in gallbladder carcinomas in vivo and in vitro. J Exp Clin Cancer Res. 2011, 30: 46-10.1186/1756-9966-30-46.CrossRefPubMedPubMedCentral
34.
Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K, Konishi F: Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer. 2002, 99: 821-828. 10.1002/ijc.10423.CrossRefPubMed
35.
Wu N, Zhao X, Liu M, Liu H, Yao W, Zhang Y, Cao S, Lin X: Role of microRNA-26b in glioma development and its mediated regulation on EphA2. PLoS One. 2011, 6: e16264-10.1371/journal.pone.0016264.CrossRefPubMedPubMedCentral
36.
Liu W, Xu G, Ma J, Jia W, Li J, Chen K, Wang W, Hao C, Wang Y, Wang X: Osteopontin as a key mediator for vasculogenic mimicry in hepatocellular carcinoma. Tohoku J Exp Med. 2011, 224: 29-39. 10.1620/tjem.224.29.CrossRefPubMed
37.
Vartanian AA, Stepanova EV, Gutorov SL, Solomko ES, Grigorieva IN, Sokolova IN, Baryshnikov AY, Lichinitser MR: Prognostic significance of periodic acid-schiff-positive patterns in clear cell renal cell carcinoma. Can J Urol. 2009, 16: 4726-4732.PubMed
38.
Wang W, Lin P, Han C, Cai W, Zhao X, Sun B: Vasculogenic mimicry contributes to lymph node metastasis of laryngeal squamous cell carcinoma. J Exp Clin Cancer Res. 2010, 29: 60-10.1186/1756-9966-29-60.CrossRefPubMedPubMedCentral
39.
Zhu P, Ning Y, Yao L, Chen M, Xu C: The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia. J Exp Clin Cancer Res. 2010, 29: 124-10.1186/1756-9966-29-124.CrossRefPubMedPubMedCentral
40.
Li M, Gu Y, Zhang Z, Zhang S, Zhang D, Saleem AF, Zhao X, Sun B: Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol Oncol Res. 2010, 16: 259-266. 10.1007/s12253-009-9220-7.CrossRefPubMed
41.
Gray DR, Huss WJ, Yau JM, Durham LE, Werdin ES, Funkhouser WK, Smith GJ: Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis. Cancer Res. 2004, 64: 1712-1721. 10.1158/0008-5472.CAN-03-2700.CrossRefPubMed
42.
Kumada T, Tsuneyama K, Hatta H, Ishizawa S, Takano Y: Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. Mod Pathol. 2004, 17: 1141-1149. 10.1038/modpathol.3800165.CrossRefPubMed
43.
Ahmadi SA, Moinfar M, Gohari Moghaddam K, Bahadori M: Practical application of angiogenesis and vasculogenic mimicry in prostatic adenocarcinoma. Arch Iran Med. 2010, 13: 498-503.PubMed
44.
Yue WY, Chen ZP: Does vasculogenic mimicry exist in astrocytoma?. J Histochem Cytochem. 2005, 53: 997-1002. 10.1369/jhc.4A6521.2005.CrossRefPubMed
45.
46.
Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, Scambia G: Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer. 2008, 18: 506-514. 10.1111/j.1525-1438.2007.01056.x.CrossRefPubMed
47.
Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008, 15: 504-514. 10.1038/sj.cdd.4402283.CrossRefPubMed
48.
Xu YH, Zhang GB, Wang JM, Hu HC: B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis. Saudi Med J. 2010, 31: 980-986.PubMed
49.
Woo T, Okudela K, Mitsui H, Yazawa T, Ogawa N, Tajiri M, Yamamoto T, Rino Y, Kitamura H, Masuda M: Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol. 2010, 4: 32-42.PubMedPubMedCentral
50.
Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I: CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer. 2010, 126: 950-958.PubMed
51.
Schneider M, Huber J, Hadaschik B, Siegers GM, Fiebig HH, Schüler J: Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker. BMC Cancer. 2012, 12: 96-10.1186/1471-2407-12-96.CrossRefPubMedPubMedCentral
52.
Immervoll H, Hoem D, Sakariassen PØ, Steffensen OJ, Molven A: Expression of the “stem cell marker” CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer. 2008, 8: 48-10.1186/1471-2407-8-48.CrossRefPubMedPubMedCentral
53.
Horst D, Kriegl L, Engel J, Kirchner T, Jung A: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 2008, 99: 1285-1289. 10.1038/sj.bjc.6604664.CrossRefPubMedPubMedCentral
54.
Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K: Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract. 2008, 62: 1212-1218. 10.1111/j.1742-1241.2008.01777.x.CrossRefPubMed
55.
Fan L, He F, Liu H, Zhu J, Liu Y, Wang L, Guo Y, Wang Z, Yan Q, Huang G: CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma. BMC Cancer. 2011, 11: 320-10.1186/1471-2407-11-320.CrossRefPubMedPubMedCentral
56.
Karbanová J, Missol-Kolka E, Fonseca AV, Lorra C, Janich P, Hollerová H, Jászai J, Ehrmann J, Kolár Z, Liebers C, Arl S, Subrtová D, Freund D, Mokry J, Huttner WB, Corbeil D: The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J Histochem Cytochem. 2008, 56: 977-993. 10.1369/jhc.2008.951897.CrossRefPubMedPubMedCentral
57.
Leta K, Tanaka F, Haraguchi N, Kita Y, Sakashita H, Mimori K, Matsumoto T, Inoue H, Kuwano H, Mori M: Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol. 2008, 15: 638-648. 10.1245/s10434-007-9605-3.CrossRef
58.
Folberg R, Maniotis AJ: Vasculogenic mimicry. APMIS. 2004, 112: 508-525. 10.1111/j.1600-0463.2004.apm11207-0810.x.CrossRefPubMed
59.
Sun B, Qie S, Zhang S, Sun T, Zhao X, Gao S, Ni C, Wang X, Liu Y, Zhang L: Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. Hum Pathol. 2008, 39: 445-451.CrossRef
60.
Han C, Sun B, Wang W, Cai W, Lou D, Sun Y, Zhao X: Overexpression of microtubule-associated protein-1 light chain 3 is associated with melanoma metastasis and vasculogenic mimicry. Tohoku J Exp Med. 2011, 223: 243-251. 10.1620/tjem.223.243.CrossRefPubMed
61.
Mineo TC, Ambrogi V, Baldi A, Rabitti C, Bollero P, Vincenzi B, Tonini G: Prognostic impact of VEGF, CD31, CD34 and CD105 expression and tumor vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol. 2004, 57: 591-597. 10.1136/jcp.2003.013508.CrossRefPubMedPubMedCentral
62.
Hilbe W, Dirnhofer S, Oberwasserlechner F, Schmid T, Gunsilius E, Hilbe G, Wöll E, Kähler CM: CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol. 2004, 57: 965-969. 10.1136/jcp.2004.016444.CrossRefPubMedPubMedCentral
63.
EI Hallani S, Boisselier B, Peglion F, Rousseau A, Colin C, Idbaih A, Marie Y, Mokhtari K, Thomas JL, Eichmann A, Delattre JY, Maniotis AJ, Sanson M: A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain. 2010, 133: 973-982. 10.1093/brain/awq044.CrossRef
Metadata
Title
Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry
Authors
Shiwu Wu
Lan Yu
Danna Wang
Lei Zhou
Zenong Cheng
Damin Chai
Li Ma
Yisheng Tao
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-535

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Research article

Gonadotropin-releasing hormone receptor activates GTPase RhoA and inhibits cell invasion in the breast cancer cell line MDA-MB-231

Research article

Alcohol consumption and risk of gastric cancer: a cohort study of men in Kaunas, Lithuania, with up to 30 years follow-up

Research article

Genetic polymorphisms in the osteopontin promoter increases the risk of distance metastasis and death in Chinese patients with gastric cancer

Study protocol

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial

Research article

Enhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancer

Debate

Has the time to come leave the “watch-and-wait” strategy in newly diagnosed asymptomatic follicular lymphoma patients?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits